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SUMMARY
Pten negatively regulates the phosphatidylinositol 3-kinase (PI3K) pathway and is required to maintain quiescent adult hematopoietic
stem cells (HSCs). Pten has been proposed to regulate HSCs cell autonomously and non-cell autonomously, but the relative importance
of eachmechanismhas not been directly tested. Furthermore, the cytokines that activate the PI3K pathway upstream of Pten are not well
defined. We sought to clarify whether Pten cell autonomously or non-cell autonomously regulates HSC mobilization. We also tested
whether Pten deficiency affects the HSC response to granulocyte colony-stimulating factor (G-CSF) and interferon-a (IFNa) since these
cytokines induce HSC mobilization or proliferation, respectively. We show that Pten regulates HSC mobilization and expansion in the
spleen primarily via cell-autonomousmechanisms. Pten-deficient HSCs do not require G-CSF tomobilize, although they are hyper-sensi-
tized to even low doses of exogenous G-CSF. Pten-deficient HSCs are similarly sensitized to IFNa. Pten therefore modulates the HSC
response to inflammatory cytokines.
INTRODUCTION
The balance between hematopoietic stem cell (HSC) prolif-
eration and quiescence is tightly regulated (He et al., 2009).
Adult HSCs are usually quiescent, but their proliferation
rates increase upon exposure to cytokines (Baldridge
et al., 2010; Essers et al., 2009; Morrison et al., 1997;
Schuettpelz et al., 2014), bacterial infections (Rodriguez
et al., 2009), and mutations that hyper-activate mito-
genic pathways such as the phosphatidylinositol 3-kinase
(PI3K) and Ras pathways (Kharas et al., 2010; Van Meter
et al., 2007; Yilmaz et al., 2006; Zhang et al., 2006). Tran-
sient proliferation maintains the HSC pool and supports
hematopoiesis, but sustained proliferation impairs HSC
function and reduces long-term self-renewal capacity
(Baldridge et al., 2010; Essers et al., 2009; Kharas et al.,
2010; Rodriguez et al., 2009; Schuettpelz et al., 2014; Van
Meter et al., 2007; Yilmaz et al., 2006; Zhang et al., 2006).
Adult HSCs therefore require mechanisms to promote
quiescence.
The PI3K pathway regulates cell metabolism, survival,
and proliferation (Luo et al., 2003), and it arbitrates the bal-
ance between adult HSC quiescence and proliferation (Lee
et al., 2010; Magee et al., 2012; Yilmaz et al., 2006; Zhang
et al., 2006). PI3K signal transduction increases in mouse
HSCs after conditional Pten deletion (Lee et al., 2010; Ma-
gee et al., 2012; Yilmaz et al., 2006; Zhang et al., 2006).
Pten-deficient HSCs proliferate at increased rates andmobi-
lize to extramedullary organs such as the spleen. They are
functionally impaired and only transiently reconstitute
irradiated mice (Lee et al., 2010; Magee et al., 2012; Yilmaz
et al., 2006; Zhang et al., 2006). Similar phenotypes have
been observed with other PI3K-pathway-activating muta-
tions, including Tsc1 deletion, Itpkb deletion, or constitu-
tive AKT expression (Gan et al., 2008; Kharas et al., 2010;
Siegemund et al., 2015). The effects of Pten deletion on
HSC proliferation and function are mediated by the kinase
mammalian target of rapamycin (mTOR) via two com-
plexes, mTORC1 and mTORC2 (Kalaitzidis et al., 2012;
Lee et al., 2010; Magee et al., 2012; Yilmaz et al., 2006).
mTOR impairs self-renewal by inducing p16 and p53
expression (Lee et al., 2010) and by inducing aberrantly
high rates of protein synthesis (Signer et al., 2014).
Together, these findings show that Pten is crucial for inhib-
iting the PI3K/mTOR pathway in HSCs, and sustained acti-
vation of the pathway compromises HSC function.
Pten has been proposed to regulate HSCs cell autono-
mously and non-cell autonomously (Tesio et al., 2013; Yil-
maz et al., 2006). Several studies have noted that Pten-defi-
cient HSCs have elevated PI3K pathway activity, consistent
with a cell-autonomous function (Kalaitzidis et al., 2012;
Lee et al., 2010; Magee et al., 2012; Signer et al., 2014).
However, Pten-deficient myeloid cells have recently been
shown to express high levels of granulocyte colony-stimu-
lating factor (G-CSF) and other pro-inflammatory cyto-
kines that canmobilize HSCs and deplete the bonemarrow
HSC pool (Tesio et al., 2013). Csf3-deficient mice (null for
G-CSF) had reduced HSC mobilization following condi-
tional Pten deletion, suggesting that Pten expression in
myeloid cells non-cell autonomously regulates HSCs by
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suppressing G-CSF production (Tesio et al., 2013). These
cell-autonomous and non-cell-autonomous mechanisms
are not mutually exclusive, but their relative importance
to HSC regulation has not been directly tested. Further-
more, a primary conclusion by Tesio et al. was that Pten
lacks any HSC-autonomous function, in contrast to prior
conclusions (Yilmaz et al., 2006; Zhang et al., 2006).
Since Pten regulates many cellular processes that are
thought to be relevant for HSC self-renewal—including
PI3K signal transduction, metabolism, protein synthesis,
and proliferation—we sought to clarify whether it func-
tions primarily via cell-autonomous or non-cell-autono-
mous mechanisms. Furthermore, we tested whether Pten
interacts with two cytokines that are known to induce
HSC proliferation and mobilization: G-CSF and inter-
feron-a (IFNa). We found that Pten regulates HSCmobiliza-
tion and expansion in the spleen primarily via cell-autono-
mous mechanisms, although non-cell-autonomous effects
were also observed. In our hands, Csf3 deletion did not
impair Pten-deficient HSCmobilization, in contrast to prior
findings (Tesio et al., 2013). However, Pten-deficient HSCs
were hyper-sensitized to G-CSF such that even low doses
of the cytokine caused a marked increase in spleen HSCs.
Higher G-CSF doses almost completely depleted Pten-
deficient HSCs from the bone marrow without further ex-
panding the spleen HSC pool. Pten-deficient HSCs were
also sensitized to mobilizing effects of IFNa. Both G-CSF
and IFNa hyper-activated the PI3K pathway in Pten-defi-
cient HSCs. Together, our data show that Pten regulates
HSCs by acting downstream rather than upstream of in-
flammatory cytokines, and it modulates the HSC response
to G-CSF and IFNa.
RESULTS
Pten Cell Autonomously Suppresses Expansion of
Spleen HSCs
To test whether Pten cell autonomously or non-cell auton-
omously regulates HSC mobilization and expansion, we
transplanted 300,000 Cre control or Ptenf/f;Mx1-Cre bone
marrow cells (CD45.2) and 300,000 wild-type competitor
cells (CD45.1) into irradiated CD45.1 recipient mice (Fig-
ure 1A). Six weeks after the transplants we administered
poly-inosine:poly-cytosine (pIpC) (3 doses, 10 mg/dose
every other day) to delete Pten. We measured bone marrow
and spleen CD45.2+ and CD45.1+ HSC (CD150+CD48
LineageSca1+c-Kit+) frequencies 14 days after Cre induc-
tion. The bone marrow of recipient mice had similar
numbers of donor CD45.2+ and competitor CD45.1+
HSCs irrespective of genotype (Figure 1B). In contrast, the
spleens of Ptenf/f;Mx1-Cre recipients had a50-fold increase
in donor HSCs after Pten deletion, relative to control
recipients, while competitor spleen HSCs increased by
only 3-fold (Figure 1C). Pten-deficient myeloid cell
(CD11b+Gr1+) frequencies increased in the spleens of recip-
ient mice, but competitor myeloid cell frequencies did
not change (Figure 1D). Pten therefore regulates expansion
of the spleen HSC and myeloid populations primarily via
cell-autonomous mechanisms, with only minor contribu-
tions from non-cell-autonomous mechanisms.
Pten has been shown to inhibit G-CSF expression in
myeloid cells (Tesio et al., 2013), but it is not clear whether
myeloid Pten expression is actually critical for suppressing
HSC mobilization. To test this, we deleted Pten in myeloid
cells with Lysozyme M-Cre (Lyz-Cre), and wemeasured bone
marrow and spleen HSC frequencies at 8–10 weeks after
birth. As positive controls we measured bone marrow and
spleen HSCs in pIpC-treated Ptenf/f;Mx1-Cre mice (which
lack Pten in all hematopoietic cells) and G-CSF-treated
wild-type mice (3.8 mg/mouse twice daily for 7 days).
Ptenf/f;Lyz-Cre mice had only modest increases in spleen
weights, spleen HSC frequencies, and spleen HSC numbers
relative to controls. They had no change in bone marrow
HSC frequencies despite efficient, myeloid-specific Pten
deletion (Figures 1E–1G and S1). In contrast, Ptenf/f;Mx1-
Cre and G-CSF-treated mice had much larger increases in
spleen HSC numbers and a concomitant reduction in
bone marrow HSCs (Figures 1F and 1G). These findings
again show that the non-cell-autonomous effects of Pten
deletion on HSCs are small when compared with the cell-
autonomous effects.
Pten Deficiency Enhances G-CSF-Induced HSC
Mobilization and Depletion
G-CSF has been proposed as a key mediator of Pten-defi-
cient HSC mobilization, but systemic G-CSF levels have
not been previously measured in Pten-deleted mice. To bet-
ter understand how G-CSF levels change following Pten
deletion, we gave pIpC to 6-week-old control and Ptenf/f;
Mx1-Cre mice (3 doses, 10 mg/dose every other day), and
wemeasured serumG-CSF levels 14 days later. As a positive
control, we administered lipopolysaccharide (LPS) to wild-
type mice as previously described (Boettcher et al., 2014).
LPS has been shown to induce G-CSF expression in endo-
thelial cells (Boettcher et al., 2014; Burberry et al., 2014).
We found that Ptenf/f;Mx1-Cre mice had significantly
elevated G-CSF levels relative to controls, but the levels
were much lower than those observed in LPS-treated
mice (Figure 2A). This raised the question of whether low
G-CSF levels are necessary and/or sufficient to mobilize
Pten-deficient HSCs.
To test whether G-CSF is necessary to mobilize Pten-
deficient HSCs, we administered pIpC to: (1) Csf3+/, (2)
Csf3/, (3) Ptenf/f;Csf3+/;Mx1-Cre, and (4) Ptenf/f;Csf3/;
Mx1-Cre littermates. After 14 days we measured bone
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marrow and spleen myeloid cell frequencies and HSC
numbers. As expected, Ptenf/f;Csf3/;Mx1-Cre (G-CSF
null) mice had significantly lower bonemarrow and spleen
myeloid cell frequencies as compared with Ptenf/f;Csf3+/;
Mx1-Cre (G-CSF heterozygous) mice (Figures 2B and S2A),
consistent with the established role for G-CSF inmyelopoi-
esis. In contrast, Ptenf/f;Csf3+/;Mx1-Cre and Ptenf/f;Csf3/;
Mx1-Crehad similar bonemarrow and spleenHSCnumbers
following Pten deletion, and spleen HSC numbers were
greatly expanded in both genotypes of mice relative to
Cre controls (Figures 2C and S2B). Thus, G-CSF is not
required to mobilize Pten-deficient HSCs to the spleen.
We next tested whether Pten-deficient HSCs are hyper-
sensitive to the mobilizing effects of G-CSF, even though
G-CSF is not absolutely required for mobilization. We
deleted Pten from 6-week-old mice, and 2 weeks later we
began a 7 day course of vehicle, low-dose (0.5 mg/day) or
high-dose (5 mg/day) G-CSF. We then measured bone
marrow and spleen HSC numbers. Low-dose G-CSF treat-
ment caused a dramatic increase in spleen HSC numbers
in Pten-deleted mice (Figure 2D). High-dose G-CSF treat-
ment almost completely depleted the bone marrow HSC
pool in Pten-deletedmice without further increasing spleen
HSC numbers (Figures 2D and 2E). These effects of G-CSF
were far more severe than those observed in wild-type
mice (Figures 2D and 2E). Interestingly, Rictor deletion did
not impair HSC mobilization at either G-CSF dose (Figures
2D and 2E). Thus, Pten modulates the HSC response to
G-CSF, but the PI3K pathway (or at least mTORC2) is not
required for physiologic HSC mobilization.
Figure 1. Pten Cell Autonomously Regulates HSC Mobilization to the Spleen
(A) Schematic overview of transplantation assay.
(B–D) Chimeric recipient mice had similar numbers of donor (CD45.2) and recipient (CD45.1) HSCs (B). Pten deletion expanded the donor
spleen HSC (CD150+CD48LSK) population to a greater extent than the recipient HSC population (C). Donor spleen Cd11b+Gr1+ myeloid cell
frequencies were also disproportionately expanded following Pten deletion (D); n = 9 control, 11 Pten D/D.
(E–G) Ptenf/f;Lyz-Cre mice had significantly lower spleen weights (E), spleen HSC frequency (F), and spleen HSC numbers (G) when
compared with Ptenf/f;Mx1-Cre and G-CSF-treated mice; n = 5–11 mice per genotype or treatment.
For all panels, error bars reflect SD and p values were calculated by two-tailed Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2. Pten-Deficient HSCs Do Not Require G-CSF to Mobilize to the Spleen, yet They Are Hyper-Sensitive to Its Effects
(A) Serum G-CSF concentrations in control, Ptenf/f;Mx1-Cre, and LPS-treated mice; n = 4–9 per genotype or treatment.
(B and C) Csf3 deletion significantly reduced spleen myeloid cell frequencies after Pten deletion (B), but it did not affect spleen HSC
numbers (C); n = 5–9 per genotype.
(D) Pten deletion withMx1-Cre and low-dose G-CSF synergistically expanded the spleen HSC population. Pten deletion with Lyz-Cre had only
minimal effects on spleen HSC numbers. Rictor deletion did not impede G-CSF mediated HSC mobilization.
(E) Pten deletion withMx1-Cre in conjunction with G-CSF treatment (5 mg/day for 7 days) almost completely depleted the bone marrow HSC
pool. Pten deletion with Lyz-Cre had no effect on bone marrow HSCs. Rictor deletion prevented G-CSF-mediated depletion of the bone
marrow HSC pool.
(F) Pten deletion enhanced HSC mobilization to the peripheral blood following treatment with low-dose G-CSF (0.5 mg/day for 5 days);
n = 4–6.
(G) Pten deletion enhanced mobilization of AMD3100-treated HSCs; n = 4–8.
(H) Western blot of 30,000 sorted HSC/MPPs. G-CSF treatment caused increased phosphorylation of AKT and S6, but only in Pten-deficient
HSCs/MPPs.
(legend continued on next page)
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G-CSF induces physiologic HSCmobilization by binding
the G-CSF receptor on monocyte-macrophage lineage cells
that, in turn, modulate stromal levels of CXCL12 (Christo-
pher et al., 2011; Day et al., 2015; Liu et al., 2000).We there-
fore tested whether Pten-deficient myeloid cells could indi-
rectly hyper-sensitize HSCs to G-CSF. We administered
vehicle, low-, and high-dose G-CSF to Ptenf/f;Lyz-Cre adult
mice for 7 days, and wemeasured bone marrow and spleen
HSC numbers. HSCs in Ptenf/f;Lyz-Cre mice were only
modestly sensitized to G-CSF as evidenced by a small in-
crease in spleen HSC numbers after high-dose treatment,
relative to wild-type controls (Figure 2D). This change con-
trasted with the much greater effects of low- and high-dose
G-CSF on Ptenf/f;Mx1-Cre HSCs (Figures 2D and 2E). These
findings suggest that: (1) low concentrations of G-CSF
can stimulate HSC mobilization and extramedullary
expansion, (2) these effects are normally suppressed by
Pten, and (3) the mechanisms are independent of PI3K
pathway regulation in myeloid cells.
Pten-deficient HSCs proliferate in the spleen more than
G-CSF-mobilized, wild-type HSCs (Figures S2C and S2D).
The marked expansion of Pten-deficient spleen HSCs that
we observed after G-CSF treatment could reflect increased
extramedullary proliferation as opposed to increased
mobilization. To better assess mobilization without the
confounding effects of extramedullary proliferation, we
splenectomized 5-week-old wild-type and Ptenf/f;Mx1-Cre
mice. We deleted Pten 1 week later and administered
vehicle or low-dose G-CSF for 5 days beginning at 8 weeks
after birth (2 weeks after pIpC). We then measured periph-
eral blood HSC numbers by flow cytometry. Pten deletion
and G-CSF treatment both independently and synergisti-
cally increased peripheral blood HSC numbers (Figure 2F).
Pten deletion also synergistically enhanced HSC mobiliza-
tion after treatment with the CXCR4 inhibitor AMD3100
(Figure 2G). Thus, Pten suppresses HSC mobilization in
response to both low-dose G-CSF treatment and CXCR4
inhibition.
To better understand why Pten-deficient HSCs are hyper-
sensitive to G-CSF, we analyzed PI3K pathway activity in
wild-type and Pten-deficientHSCs andmultipotent progen-
itors (HSC/MPPs; CD48LSK) after 2 days of treatmentwith
vehicle, low-, or high-dose G-CSF. We assessed phosphory-
lation of AKT (an mTORC2 target) and S6 (an mTORC1
target) by western blotting. In wild-type HSC/MPPs,
G-CSF had no effect on AKTor S6 phosphorylation at either
dose (Figure 2H). In Pten-deficient HSC/MPPs, low-dose
G-CSF increased AKT phosphorylation relative to un-
treated Pten-deficient HSC/MPPs, and high-dose G-CSF
markedly increased S6 phosphorylation (Figure 2H).
Thus, G-CSF hyper-activates the PI3K/mTOR pathway in
Pten-deficient HSCs but not wild-type HSCs.
We tested whether Ptenmodulates the expression of sur-
face proteins that are known to regulate HSC homing
including CXCR4, VLA-4, and CD44 (Avigdor et al., 2004;
Rettig et al., 2012). We also characterized expression of
MT1-MMP, a matrix metalloproteinase that is expressed in
G-CSF-stimulated HSCs in an mTOR-dependent manner
and that promotes mobilization (Shirvaikar et al., 2010;
Vagima et al., 2009). Whereas G-CSF treatment caused a
modest increase in CXCR4 and CD44 expression as deter-
mined by flow cytometry (Figure 2J), Pten deletion had
no effect onCXCR4, VLA-4, or CD44 expression (Figure 2I).
Likewise, MT1-MMP expression was elevated in G-CSF-
mobilized HSCs, consistent with prior studies (Shirvaikar
et al., 2010; Vagima et al., 2009), but it was not changed
in Pten-deficient HSCs (Figure 2K).
Our data suggest that G-CSF mobilizes and expands
Pten-deficient spleen HSCs through mechanisms that are
distinct from its normal physiologic activity. HSCs likely
require Pten to keep low levels of G-CSF and other in-
flammatory cytokines from hyper-activating the PI3K/
mTOR pathway. This observation is consistent with
prior data showing that mobilization and extramedullary
expansion of Pten-deficient HSCs requiresmTORC2 (Magee
et al., 2012), while physiologic mobilization does not
(Figure 2D).
Pten Deficiency Enhances pIpC-Induced HSC
Mobilization
In light of the observed interaction between Pten and
G-CSF, we tested whether Pten also modulates the HSC
response to IFNa. This hypothesis was based on prior
data showing that IFNa induces AKT phosphorylation in
less-pure progenitor populations (Essers et al., 2009) and
recognition of the fact that interferon signaling, like Pten
deletion, drives HSCs into cycle and depletes the HSC
pool (Baldridge et al., 2010; Walter et al., 2015). Further-
more, Ptenf/f;Mx1-Cre mice (which require pIpC-induced
IFNa signaling to delete the Pten allele) have been shown
to have more severe HSC phenotypes than tamoxifen-
inducible Ptenf/f;Scl-CreER mice (Tesio et al., 2013). This
(I and J) Pten deletion did not cause differences in CXCR4, CD49d, or CD44 expression in HSCs (I), while G-CSF treatment caused increased
CXCR4 and CD44 expression in mobilized spleen HSCs (J); n = 3–6.
(K) G-CSF, but not Pten deletion, stimulated MT1-MMP expression; n = 4–5.
For all panels, error bars reflect SDs and p values were calculated by two-tailed Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001;
(D and E) #p < 0.05 for 0.5 mg/day G-CSF versus 0 mg/day G-CSF for the indicated genotypes; ##p < 0.05 for 5 mg/day G-CSF versus
0.5 mg/day and 0 mg/day G-CSF for the indicated genotypes; n = 4–16.
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raised the question of whether pIpC treatment contributes
to the phenotypes observed in Ptenf/f;Mx1-Cre mice.
We first tested whether pIpC activates the PI3K pathway
in wild-type and Pten-deficient HSCs. We gave three doses
of pIpC (10 mg/dose) to 6-week-old wild-type and Ptenf/f;
Mx1-Cre mice to delete Pten. Two weeks later, we treated
the mice with vehicle or a single additional 10 mg dose
of pIpC to re-induce IFNa. We isolated HSC/MPPs 24 hr
later and performed western blots to assess PI3K pathway
activity. HSC/MPPs from wild-type mice that received
the additional pIpC dose (hereafter called pIpC-treated)
had high AKT and S6 phosphorylation relative to controls
that did not receive the additional dose (Figure 3A).
S6 phosphorylation was even higher in pIpC-treated,
Pten-deficient HSC/MPPs (Figure 3A). STAT1, a known
IFNa target, was also more highly phosphorylated in
pIpC-treated HSC/MPPs, consistent with prior studies (Ess-
ers et al., 2009). These data show that IFNa induces PI3K/
mTOR signaling in HSCs and that its effect on mTORC1/
S6K signaling is greater in Pten-deficient HSCs than in
wild-type HSCs.
We next devised a strategy to delete Pten without pIpC
so that we could characterize the interaction between
Pten and IFNa independently of Cre induction. We iso-
lated HSCs from E16.5 Ptenf/f mice and treated half of
the cells with Tat-Cre for 30 min ex vivo to delete Pten
(Figure 3B). We transplanted control or Tat-Cre-treated
HSCs into irradiated recipients (350 HSCs and 300,000
competitor bone marrow cells per recipient). Unlike adult
HSCs, Pten-deficient fetal HSCs were able to reconstitute,
consistent with previously published findings (Magee
et al., 2012). Six weeks after the transplants we adminis-
tered pIpC to half of the mice (three doses, 10 mg/dose
every other day). Two weeks later we measured spleen
cellularity and HSC frequencies. pIpC caused a signifi-
cant increase in spleen cellularity and spleen HSC fre-
quency in recipients of Tat-Cre-treated HSCs, but bone
marrow HSC frequencies did not differ between the treat-
ment groups (Figures 3C and 3D). Spleen HSC numbers
were significantly increased in recipients of Tat-Cre-
treated HSCs, and this value further increased after
pIpC treatment (Figure 3E). Thus, Pten modulates the
Figure 3. Pten-Deficient HSCs Are Mobilized by pIpC Treatment
(A) Western blot of 30,000 HSC/MPPs after pIpC treatment to delete Pten followed by a single vehicle or pIpC dose 2 weeks later to
induce IFNa.
(B) Schematic overview for Tat-Cre-mediated deletion of Pten followed by pIpC treatment.
(C–E) pIpC treatment resulted in a significant increase in the spleen cellularity (C), spleen HSC frequency (D), and spleen HSC numbers (E)
in recipients of Tat-Cre-treated Ptenf/f HSCs. (C–E) n = 4–7 for each genotype and treatment.
Error bars reflect SDs and p values were calculated by two-tailed Student’s t test; *p < 0.05, **p < 0.01, ***p < 0.001.
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HSC response to IFNa, much like it modulates the
response to G-CSF.
DISCUSSION
We have conducted experiments to clarify whether Pten
regulates HSCs cell autonomously or non-cell autono-
mously. Our data confirm that Pten regulates HSCs via
both cell-autonomous and non-cell-autonomous mecha-
nisms (Figure 1). The data also show that the cell-autono-
mous effects of Pten deletion are significantly greater than
the non-cell-autonomous effects (Figure 1). While our ana-
lyses of Ptenf/f;Csf3/;Mx1-Cremice do not support an obli-
gate role for G-CSF in HSC mobilization (Figure 2C), we
have found that Pten-deficient HSCs are hyper-sensitive
to the mobilizing and depleting effects of G-CSF (Figures
2D and 2E). This hyper-sensitivity does not appear to
reflect enhancement of normal physiologic mobilization
mechanisms. Rather, G-CSF enhances PI3K/mTOR
pathway activation in HSCs that lack Pten (Figure 2H).
This could occur through direct engagement of the G-CSF
receptor or through indirect activation of other cytokines
in the microenvironment. Pten-deficient HSCs also hyper-
activate mTORC1/S6K and mobilize in response to IFNa
(Figure 3). Together, these data suggest that Ptenmodulates
the HSC response to inflammatory cytokines, and pIpC
contributes to the HSC proliferation, mobilization, and
self-renewal phenotypes that have been widely described
using Ptenf/f;Mx1-Cre mice (Kalaitzidis et al., 2012; Lee
et al., 2010; Magee et al., 2012; Signer et al., 2014; Yilmaz
et al., 2006; Zhang et al., 2006).
Our data potentially link two major modes of HSC
regulation—the PI3K pathway and pro-inflammatory cyto-
kines—as common causes of HSC depletion during illness
or aging. The consequences of PI3K pathway activation
in HSCs have been extensively studied (Gan et al., 2008;
Kharas et al., 2010; Lee et al., 2010; Magee et al., 2012; Sie-
gemund et al., 2015; Signer et al., 2014), but the signals that
activate the pathway—either in native or stressed condi-
tions—have not been well characterized. Likewise, inflam-
matory signals have drawn scrutiny for their putative role
in bone marrow failure, HSC aging, and pre-leukemic
clonal evolution (Baldridge et al., 2010, 2011; Essers et al.,
2009; Walter et al., 2015), but the downstream mecha-
nisms by which these signals deplete HSCs have not been
fully resolved. Our data suggest a model in which inflam-
matory cytokines hyper-activate the PI3K pathway in
HSCs leading to increased protein synthesis and tumor-
suppressor expression, which ultimately depletes the HSC
pool. Ongoing experiments will test whether mTORC1
or mTORC2 inactivation can preserve the function of
cytokine-stimulated HSCs. If so, mTOR inhibitors may
have a role in sustaining the HSC pool in patients with
inflammation and otherwise tenuous HSC function (e.g.,
bone marrow transplant patients with complicating graft-
versus-host disease or infections).
EXPERIMENTAL PROCEDURES
Mouse Strains and Injections
The Ptenf/f, Rictorf/f, Mx1-Cre, and Lyz-Cre strains have been
described previously and are available from The Jackson Labora-
tory (Clausen et al., 1999; Groszer et al., 2006; Kuhn et al., 1995;
Magee et al., 2012). Expression of Mx1-Cre was induced by three
intraperitoneal injections of pIpC (GE Life Sciences; 10 mg/dose)
over 5 days beginning 6 weeks after birth. Recombinant human
G-CSF (Amgen) was given subcutaneously at the doses noted in
the text and figure legends. AMD3100 (Genzyme)was given subcu-
taneously at 5 mg/kg 2 hr before euthanizing the mice, as previ-
ously described (Devine et al., 2008). All mice were housed in the
Department for Comparative Medicine at Washington University.
All animal procedures were approved by the Washington Univer-
sity Committees on the Use and Care of Animals.
Isolation of HSCs, Flow Cytometry, and HSC
Transplantation
HSCs were isolated, analyzed, and transplanted as described previ-
ously (Magee et al., 2012), and as described in detail in the Supple-
mental Experimental Procedures.
G-CSF Measurements
Serum G-CSF levels were measured with the mouse G-CSF Quanti-
kine ELISA Kit (R&D Systems). For positive controls, mice were
injected with 35 mg of LPS at 72 and 24 hr prior to sacrifice, as
described previously (Boettcher et al., 2014).
Western Blots
Western blotswere performed as described previously (Magee et al.,
2012) and in the Supplemental Experimental Procedures.
Tat-Cre Treatments
Fetal Ptenf/f HSCs were sorted into 0.1 ml of Iscove’s modified
Dulbecco’s medium with 2% fetal bovine serum and incubated
with 30 units of Tat-Cre (Millipore) for 30min at 37C. A complete
description of the optimization protocol is provided in the
Supplemental Experimental Procedures (Figure S3).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and three figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2016.04.008.
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